Jiang R, et al. - Researchers assessed the risk-benefits of low-intensity warfarin therapy by analyzing data from randomized control trials (RCTs), identified via a search of electronic databases from inception through June 2016. They included studies that reported efficacy (recurrent venous thromboembolism [VTE]) and safety (bleeding episodes) of low-intensity warfarin therapy vs conventional-intensity warfarin or placebo. Overall, they analyzed four RCTs reporting high GRADE quality evidence. Findings revealed that long-term low-intensity warfarin therapy vs placebo was a highly effective option for preventing recurrent VTE. It also reduced risks of major bleeding and minimized potential complications. However, when compared with conventional-intensity warfarin therapy, long-term low-intensity warfarin therapy was found to be less effective.